Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Eyconis INC.
Summary
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Eligibility
- Age range
- 50+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Known hypersensitivity or known allergy that would preclude study drug administration * Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access * Uncontrolled diabetes mellitus * History of cerebrovascular accident (CVA) or myocardial infarc…
Interventions
- BiologicalEYC-0305